About
DNA Damage Response Therapies
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (3)
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
5
As Collaborator
3
Total Enrollment
1,542
By Phase
PHASE2: 3PHASE1/PHASE2: 2NA: 1PHASE1: 1
By Status
COMPLETED: 3ACTIVE_NOT_RECRUITING: 2RECRUITING: 2TERMINATED: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT05798611Lead Sponsor
Study of ART0380 in Patients With Biologically Selected Solid Tumors
PHASE2Terminated
36 participants
Started: Sep 6, 2023 · Completed: May 27, 2025
NCT05898399Lead Sponsor
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
PHASE1/PHASE2Active, not recruiting
220 participants
Started: Jun 30, 2023 · Completed: Dec 14, 2026
NCT05378204Collaborator
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
NARecruiting
120 participants
Started: Jun 23, 2022 · Completed: Jun 30, 2027
NCT04991480Lead Sponsor
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
PHASE1Active, not recruiting
390 participants
Started: Sep 13, 2021 · Completed: Mar 31, 2026
NCT04976803Lead Sponsor
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
N/ACompleted
229 participants
Started: May 28, 2021 · Completed: Jun 30, 2022
Locations (1)
Headquarters
Cambridge, UK
Map
Loading map...